The aim of this study was to determine the existence of association between the genetic polymorphisms of metabolizing genes GSTM-1, GSTT-1, and NAT-2, and the presence of mitochondrial genome instability (mtGI) in breast cancer cases. Ninety-four pairs of tumoral/nontumoral breast cancer samples were analyzed. Our samples showed 40.42% of mtGI by analysis of two D-loop re gion markers, a (CA)n mtMS starting at the 514-bp position, and four informative Mnl\ sites between the 16,108-16,420-bp. GSTM-1 null genotype has shown a significant association with mtGI presence (x2 = 7.62; P = 0.006) in breast cancer cases; moreover, these genotypes also are related to an increased risk for mtDNA damage (odds ratio (OR) =3.71 (1.41-9.88); 95% Cornfield confidence interval (Cl)). These results suggest that the absence of GSTM-1 enzymatic activity favors chemical actions in damaging the mtDNA. Analysis of GSTT-1 and NAT-2 polymorphisms showed no association with mtGI (x2 = 0.03; P = 0.87 and x2 = 2.76; P = 0.09, respectively). The analysis of invasive breast cancer cases showed mtGI in 74.36% of ILC cases (29 of 39 samples), and in only 18.75% (9 out of 48) IDC cases; this result suggests a possible relation between mtDNA mutations and variations in molecular path ways of tumor development.
INTRODUCTION
Worldwide, breast cancer is the fifth most common cause of cancer death and the first cause among women (1) . Ap proximately 40% of breast cancer cases show nuclear genome instability (NGI), due to the malfunction of one or more genes forming the cohort of mismatch re pair genes (MMR) (2, 3) , while more than 60% show mtGI, a second form of insta bility associated with tumors and charac terized by the presence of point muta tions or length tract instabilities in mtDNA (4, 5) .
The finding of mutations and deletions in mtDNA of tumor cells has focused the attention on these cytoplasmic organelles as concurrent factors in the start or progress of tumors (6) . However, little is known about the mtGI, their presence and frequency variation among tumors, the mechanisms involved in their origin, and their role in human cancers.
The human mtDNA is a 16,569-bp, cir cular and double-stranded molecule. All the mt genome encoded genes are orga nized continuously with noncoding in tervening sequences except for a small segment called displacement-loop (D-loop), which comprises some of the replication and transcription origins of the mt-genome (7) .
Trying to clarify the origin of mtGI and their role in human cancers, particularly in breast cancer, our group previously showed that causes of the appearance of NGI are not involved in mtGI (8) . This result was confirmed later by other work (9, 10, 11) , allowing us to conclude that NGI and mtGI are independent events with different mechanisms of origin.
Moreover, in the last year, there was significant progress regarding the func tion of the metabolizing enzymes and their role in the elimination of a very wide class of DNA damage compounds (1) . The xenobiotic metabolizing en zymes (XME) are a family of enzymes coded by the xenobiotic metabolizing genes (XMG) . There are more than twelve different families of enzymes that have been described for almost all ge netic polymorphisms that modified their activity efficiency, and that are responsi ble for wide inter-individual variation in drug metabolism (12) .
The human mammary gland is ex posed to agents capable of inflicting DNA damage and thereby initiating tumor induction (13, 14, 15) . Most of these potential human mammary carcinogens require enzyme-catalyzed steps to effect biotransformation to DNA-reactive metabolites. Although hepatic enzymes are likely to play a role in the metabo lism of potential breast carcinogens, it is important to consider that enzymes ex pressed locally in the target site also have relevant influence in modulating DNA-reactive species levels (1) .
Glutathione S-Transferase isoforms, a (GSTM-1) and r (GSTT-1), and N-Acetyl Transferase 2 (NAT-2) are enzymes which demonstrate expression in mammary tis sues (1) . For both the GST enzymes, the deficiency is due to a deletion of the en tire genomic coding region, giving rise to the allele known as "null." The dele tion in a homozygous state determines the polymorphism called "null geno type," with the consequent absence of total enzymatic activity. Regarding the NAT-2 gene, at least 19 variant alleles have been detected in the human popu lation (16) , but the NAT-2*5, *6, and *7 alleles account for virtually all of the slow acetylator alleles in the Caucasian population, providing evidence for a high concordance between genotype and phenotype (17) .
In this report, we first analyze pairs of breast non tumoral/tumoral tissues for the presence of mtGI, studying two markers of the D-loop region which have a low spontaneous rate of mutation in germline cells, a (CA)n mt MS (micro satellite) starting at the 514-bp position, and four informative Mnll sites located between the 16,108-bp and 16,420-bp po sition (8) . Second, we analyze the poly morphism of GSTM-1, GSTT-1, and NAT-2 in breast cancer patients with and without mtGI, trying to determine whether this instability is associated with a specific allele for the XMG. Further more, we analyzed the possible correla tion between the presence of mtGI and the histopathological types of breast can cer samples.
MATERIALS AND METHODS

Samples
Ninety-four breast cancer samples and their adjacent nontumoral tissues were obtained from female patients at a Clini cal Center from La Plata City (Buenos Aires, Argentina), who underwent surgi cal resection between 1997 and 2004, ac cording to the Institutional Review Board approved protocol. We have selected only those patients who did not undergo pretreatments (radioor chemotherapy) before surgery. A representative tissue section was stained with haematoxylin and eosin and semiquantitatively as sessed for tumor area percentage over the total sample area by one of the au thors (M Laguens); cancer regions se lected for DNA extraction showed >90% abnormal cells. Histological typing was based on standard criteria (18) . All the donors gave informed consent for the study. The DNA extraction was per formed using a Qiagen DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA).
mtDNA Analysis
The (CA)h MS, starting at 514 bp and showing five haploid alleles differing in size by the number of dinucleotide re peats (7) , was amplified with the primers and polymerase chain reaction (PCR) conditions reported by Szibor et al. (19) . Microsatellite allele identification was performed by electrophoresis in 15% neutral polyacrylamide and Sybr-Green fluorescence.
Restriction fragment length poly morphisms (RFLP), for Mnll sites [CCTC(,(N)7] between nontumoral (Nt) and tumoral (T) tissue, were detected in an mtDNA fragment of 312 bp extending from the 16,108 bp position to the 16,420 bp position (7) . PCR conditions and primers were as reported previously in Richard et al. (8) . According to the refer ence sequence of Anderson et al. (7) , the 312 bp fragment comprises five Mnll sites producing fragments of 118, 89, 39, 35, 28, and 3 bp. With the exception of the 3 bp fragment, which could not be identified due to its small size, all of the other fragments and their corresponding RFLP patterns were detected by elec trophoresis in 10% neutral polyacry lamide visualized by Sybr-Green fluores cence staining.
Those pairs of tumoral and nontu moral samples showing mt markers heteroplasmy and/or changes between both tissues were tested 2 to 4 times in independent studies performed by two researchers to confirm the consis tency of mt marker identifications and to exclude possible sample cross-contamination.
Analysis of Xenoblotlc Metabolizing Genes
GSTM-1 genotype analysis was car ried out by a modification of the duplex PCR procedure described by Hou et al. (20) , replacing the internal PCR-positive control reaction (NAT-2), by a segment of the syntenic gene GSTM-2 (211pb, ac cession number STS-RH65389). Primers for GSTM-2 were: Fw: 5'-TgA AgT CCT TCA ggT TTg gg -3'; Rw: 5'-CAg CCA Tgg TTT CTT CTT ggg -3', and the an nealing temperature was 58°C. This method allows us to identify individu als with one or two copies of the GSTM-1 allele (showed both the GSTM-1 and the control band), from individuals with a homozygous deletion (null genotype only amplifies the control gene). GSTT-1 genotype was deter mined using the same duplex PCR conditions and primers reported by Baranova et al. (21) . Identification of NAT-2 slow acetylators was performed by PCR method and specific restriction endonucleases analy sis as reported previously in Hou et al. (20) . The NAT-2 mutant alleles were identified by the substitution nucleo tides, and loss of a restriction site, in C481T (Kpnl), G590A (TaqI), and G857A (BamHT), allele *5, *6, and *7, respectively. The wild-type allele (NAT-2 *4) was de fined by the absence of such substitu tions. Correlation phenotype/genotype, the presence of at least one wild-type al lele, confers an intermediate acetylator phenotype (NAT2*I), whereas two mu tant alleles are required for the slow acetylator phenotype (NAT2*S). The wild-type allele in a homozygous state determines the rapid acetylator pheno type (NAT2*R) (20, 22) .
Statistical Methods
The x2 test was used to study the dif ference in the genotype distributions. Relative risk was estimated with Odds Ratio (OR) and the Cornfield 95% confi dence interval (95% CI). P values (twosided) below 0.05 or Odds Ratio with a 95% CI over or below 1.0 were consid ered statistically significant.
RESULTS mtDNA Analysis: (CA)n mtMSI and Mnl\ RFLPs In Nt/T Tissue
Over a total of 94 breast tissues ana lyzed for (CA)h MS, we detected eight heteroplasmic samples (8.51%). The analy sis of tumor sample counterparts showed allele changes in 24 of 94 cases (25.53%).
The appearance of Mull mutations was observed in 28 of 94 cases of breast can cer patients (29.79%), comparing the di gestion pattern in tumoral tissues with the nontumoral counterpart. Moreover, we observed that five of these samples showed heteroplasmy in the nontumoral tissue (presence of two different diges tion patterns).
We considered a case unstable when it had a changed allele in the mtMS, differ ence in the digestion pattern for MnlL, or both events in parallel; therefore, if we combine MS and Mull data, the mtGI ob served in cancer tissues was 38 of 94 (40.42%).
Histopathological Types of Breast Cancer and mtGI Event Analysis Association
The possible correlation was evaluated in 94 total cases, consisting of one case of LCIS (Lobular Carcinoma In Situ), 39 cases of ILC (Lobular Carcinoma Inva sive), six cases of DCIS (Ductal Carci noma In Situ), and 48 cases of IDC (Duc tal Carcinoma Invasive).
Forty-one samples from the 94 total cases analyzed showed mtGI, 29 showed ILC (70.73%), whereas only 9 cases showed IDC (21.95%), and the remaining 3 cases showed DCIS (7.32%).
Analyzing particularly invasive case results, we found mtGI in 74.36% of the 
Analysis of Xenobiotic Metabolizing Genes
None of the obtained frequencies for the xenobiotic metabolizing gene poly morphisms studied showed significant differences with data reported for the same ethnic population ( Table 1) .
Of 35 mtGI tumors, 21 (60%) were ho mozygous for the GSTM-1 null allele. In contrast, 71.2% of the samples carrying the gene in hetero-or homozygosity (42 of 59 cases) showed a stable mt genome (without detection of mutations or insta bility). Those opposite values of observed percentages indicate that the GSTM-1 null genotype may be correlated with the presence of mtDNA instability. Evaluat ing this possibility with statistical meth ods, we observed that, effectively, there was a positive significant association (x2 = 7.62; P = 0.006) for the events mentioned above (Table 2 ). Moreover, the OR value obtained (OR = 3.71 [1.41-9.88]; 95% CI), confirms the correlation between the ho mozygous deletion of the gene as a risk factor for mtGI generation.
The analysis for GSTT-1 gene showed that 32 of 94 samples analyzed showed mtGI, from which only five (15.6%) have the null genotype, whereas the remain ing 84.4% (27 of 32) carry one or two copies of the allele. Using a statistical method, we found no significant correla tion between mtGI and GSTT-1 homozy gous null (x2 = 0.03; P = 0.87), as shown in Table 2 .
Analyzing a total of 94 cases for three NAT-2 gene polymorphisms (C481T, G590A, and G857A), we found that seven cases were rapid acetylator (7.4%), 45 were intermediate acetylator (47.9%), and 42 were slow acetylators (44.7%) ( Table 1) . To analyze the possible correla tion between the acetylator type for NAT-2 and the presence of mtGI, we con sidered the intermediate and rapid acety lator together because of the small num ber of the latter. The statistical methods, evaluating the *S versus *I/*R acetyla tors, showed that there is no significant association (x2 = 2.76; P = 0.09) ( Table 2) . We also assessed, separately, the correla tion between mtGI and each of the acety lators studied (*R, *1, and *S), and we found no significant association (statisti cal data not shown). 
DISCUSSION
Mitochondrial Genome Instability
It is believed that mutations in the mi tochondrial genome contribute to the process of carcinogenesis. In recent years the existence of alterations in the mtDNA in several human cancers (gastric, colo rectal, lung, and breast) has been demon strated (23) .
We found that 38 of 94 cases (40.42%) showed mtGI when both markers from the D-Loop region were analyzed. Our group published one of the first works to evaluate the existence of mtGI in breast cancer (24) , finding mutations in the en tire mt genome of tumoral cells (5 of 7 cases), but not in nontumoral cells. Sub sequently, other works also describe the presence of mutations at the mtDNA when compared with the mammary tu moral sample and paired with adjacent nontumoral tissues from the same pa tient. Sequencing the entire mt genome, Zhu et al. (25) identified one or more so matic mutations in 14 of 15 (93%) breast cancer cases studied; while Tan et al. (26) found that 74% (14 of 19 tumors ana lyzed) displayed at least one somatic mtDNA mutation, and that 81% of the changes were in the D-loop region ( The high frequency of somatic muta tion reported for the mtDNA in breast cancer cases and the percentage of mtGI found in our series (40.42%) show that this instability is not a sporadic phenom enon, but rather is a detectable feature in a high rate of breast cancer cases studied, as well as for other carcinomas (lung, gastric, and colorectal cancers) (27) . De spite this, testicular tumors did not show mtGI (0 of 17 cases) (4), neither did blad der tumors (in a preliminary analysis we found that 0 of 10 cases studied showed this event). Consequently, this data could reflect the existence and/or succession of certain conditions that favor the mtGI generation in some tumors but not in oth ers. One explanation would be the pres ence of a barrier mechanism acting only in a particular tissue and preventing the induction of mutations locally; for exam ple, specific metabolizing enzyme(s) (1), as we will discuss later for the XMG studied in the present report.
mtGI and Breast Cancer Histopathological Type
Presently, we have found that 74.36% of ILC samples presented the mtGI phe nomenon (29 of 39 samples), while only 18.75% of total IDC samples showed this event (9 of 48 cases). A low percentage of mtGI for IDC (10.8%) was reported pre viously by Alazzouzi et al. (9) .
The possible correlation between mtGI frequencies and the histopathological features of the samples was evaluated previously by other researchers, both for breast cancer and other types of tumors. In malignant melanomas, the mtMSI in cidence increased from 3% (one case) of sporadic malignant melanomas (SSM), to 13% (four cases) of nodular melanoma (NM), and even more in metastatic melanomas (MM) with 20% (nine cases). The mtMSI was determined analyzing insertions and/or deletions at the D-310 homopolymer C tract and the MS (CA)n (nt514-nt523) (28) . Although only 4 of 37 (10.8%) ductal type breast cancer cases analyzed by Alazzouzi et al. (9) showed mtGI, 3 of the 4 cases corresponded to grade III tumors.
These data suggest that mtGI could be related to variations in molecular path ways of tumor development in breast cancer subtypes. Our results show this as well, with a higher percentage of cases with mtGI in ILC than in IDC breast cancer.
Analysis Association between mtGI and the XMG Studied
GSTM-1. We found a higher signifi cant association (y2 = 7.62; P = 0.006), be tween the null genotype and the pres ence of mtGI (OR = 3.71 [1.41-9 .88]; 95% CI) ( Table 2 ).
The finding of GSTM-1 null genotype as a susceptibility factor risk for breast cancer has been reported previously (29, 30, 31) . Helzlsouer et al. (32) reported an increased breast cancer risk in women with the null genotype (OR = 2.10 [1.22-3.64 ]; 95% CI). Charrier et al. (33) found a positive associ ation in postmenopausal women, while Ambrosone et al. (34) found a correlation between GSTM-1 null and younger post menopausal women with breast cancer. Moreover, Rebbeck et al. (35) examined breast cancer patients with a family his tory and found no association between GSTM-1 null allele and tumor risk.
However, we can point out that so far no study has analyzed its possible associ ation with mtGI event, as is done in the present report.
It is known that the GSTM-1 isoform (mu, ri) is expressed in human breast tis sue cells (1, 36) . Moreover, a study con ducted in mouse liver mitochondria demonstrates that its concentration is in duced by the presence of toxic metabo lites (as in oxidative stress conditions) in the mitochondrial matrix, as well as in the cytosolic compartment (37, 38) . These enzyme properties, along with the fact that human breast tissues are exposed to a large number of genotoxic compounds (most of which are metabolized by GSTM-1 enzyme [1] , including products such as reactive oxygen species [ROS] [37] ), support our correlation result be tween GSTM-1 null genotype and an in crease in mtGI. Gene deletion in only one allele also causes enzyme activity to de crease, so we could assume that this deletion also could be involved in mtGI generation.
Although in the present report we men tioned that GSTM-1 null genotype could be a risk factor for mtGI presence, it also is possible that GSTM-1 "+" acts as a pro tective factor for mtDNA damage. The GSTM-1 genotype distribution in cases with mtGI presence is closer to numbers reported previously; whereas GSTM-1 fre quencies in those with mtGI absence are different from the accepted limit percent ages in the literature (Tables 1,2 ). There fore we should consider the possibility of a protective role of the enzyme encoded by GSTM-1 gene rather than the null genotype as a risk factor for mitochondr ial genome damage. Figure 1 shows a hypothetical diagram about the processes that occur within the mitochondrial matrix in reference to the damage caused by reactive compounds in the presence or absence of the GSTM-1 enzyme.
GSTT-1 and NAT-2. Our results have shown that neither the GSTT-1 null geno type (P = 0.87) nor the different acetylators for NAT-2 (P = 0.09) have significant association with the presence of mtGI in 
Figure 1.
Here we diagram the possible role GSTM-1 enzyme plays inside the mitochondrial matrix as mtDNA protector factor regarding damage caused by reactive species. The bio logical systems can produce these compounds by different pathways. One of the most im portant endogenous mechanisms is the respiratory chain, generating great levels of ROS during the O2 reduction. Lipid peroxidation over the membrane lipoprotein, caused by ROS action, is another source of active compounds (HNE: 4-Hydroxynonenal, for example). An other important mechanism involved in ROS generation is the biotransformation of different exogenous compounds or xenobiotics by action of different XME. The ROS action into the cell could produce lesions in different mt compounds, such as lipids; damage different kinds of proteins, Poky for example; damage the mtDNA directly by action of these active species on the bases, or indirectly by DNA replication with a faulty Poky that introduces er rors. Altogether, those deleterious processes lead to genotoxic damage, as shown in the right side of the image. The left side shows the possible metabolic pathway of the GSTM-1 enzyme, promoting the elimination of reactive species and blocking their deleterious effect over the mt component. It is important to note the possible protective action of GSTM-1 over the mtDNA. The picture shows only a schematic pathway for the GSTM-1 enzyme; the other mitochondrial matrix events are simplified.
breast cancer samples ( Table 2) . A possi ble explanation is that, although expres sion of these genes was detected in the mammary tissue, the encoded enzymes do not show enzymatic activity inside the mitochondrial matrix (1). This allows -< GS£) Conjugated Glutathion, by GSTM-1 action, with: ÇLPÇÏXGSS) Lipoperoxides;
(ROS GS i Reactive Oxygen Species; jÂÏGS~) other xen°biotic -------or reactive compounds.
us to conclude that the action of damag ing metabolites on the mt genome is not mediated and/or regulated by these en zymes on a local level. So, the presence of mtGI in breast cancer tissues was in dependent of those XMG.
